← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Plx Opco, Inc.
Houston, TX
$6,941,683
Total funding
7
Grants
Funding over time
peak $1.2M · FY2007–19$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$6,941,683 · 7
By mechanism
R42$3,563,170 · 2
R44$2,127,711 · 2
RC3$798,642 · 1
R41$294,226 · 1
R43$157,934 · 1
Investigators at Plx Opco, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Aspirin-PC for Chemoprevention of Colorectal Cancer$966,160
R42 · FY2018 · CA
Aspirin-PC for Chemoprevention of Colorectal Cancer$961,499
R42 · FY2017 · CA
Clinical Evaluation of GI Safer Naproxen for the Treatment of Osteoarthritis$798,642
RC3 · FY2010 · AR
GI-Safer Naproxen Formulation R&D for the Treatment of Osteoarthritis and Related$745,708
R44 · FY2009 · AR
Gastrointestinal safety and therapeutics of oil-based Phosphatidylcholine-NSAIDS$566,719
R42 · FY2007 · DK
GI-Safer Formulation of Indomethacin for use in Preterm Neonates$565,449
R44 · FY2012 · HD
GI-Safer Formulation of Indomethacin for use in Preterm Neonates$552,949
R44 · FY2013 · HD
Gastrointestinal safety and therapeutics of oil-based Phosphatidylcholine-NSAIDS$501,617
R42 · FY2008 · DK
Gastrointestinal safety and therapeutics of oil-based Phosphatidylcholine-NSAIDS$464,675
R42 · FY2009 · DK
GI-Safer Naproxen Formulation R&D for the Treatment of Osteoarthritis and Related$263,605
R44 · FY2008 · AR
GI-Safer Formulation of Indomethacin for use in Preterm Neonates$157,934
R43 · FY2010 · HD
Aspirin-PC for Chemoprevention of Colorectal Cancer$147,318
R41 · FY2013 · CA
Aspirin-PC for Chemoprevention of Colorectal Cancer$146,908
R41 · FY2014 · CA
Aspirin-PC for Chemoprevention of Colorectal Cancer$65,000
R42 · FY2019 · CA
Gastrointestinal safety and therapeutics of oil-based Phosphatidylcholine-NSAIDS$37,500
R42 · FY2010 · DK